ROMATİZMAL HASTALIKLAR VE DİŞ HEKİMİ YAKLAŞIMI

Year 2018, Volume: 28 Issue: 4, 574 - 582, 14.10.2018

Selin Yeşiltepe Özkan Miloğlu İrfan Sarıca Kübra Törenek

https://doi.org/10.17567/ataunidfd.473981

Cited By: 2

Abstract

Romatizmal
hastalıklar, klinik olarak, eklem ve peri- artiküler dokuların tutulumuyla
seyreden kas-iskelet sistemine ait birçok bozukluğu kapsamaktadırlar.
Romatizmal hastalıklarda oral mukoza belirtileri, bazı hastalıklarda tanı veya
sınıflama kriterlerine girecek kadar ayrı bir öneme sahiptir. Bu hastalıkların
tedavi- sinde kullanılan ilaçlar ve etkileşimleri, hastalıkların oral mukoza ve
çene eklemlerindeki tutulumları diş hekimleri açısından önem taşımaktadır. Bu
derlemede romatizmal hastalıklar ve diş hekimi yaklaşımları ile genel bilgilere
yer verilmiştir.

Anahtar Kelimeler: Romatizmal
hastalıklar, diş hekimliği, ağız sağlığı

 

RHEUMATIC DISEASES AND
DENTIST APPROACH

ABSTRACT

Rheumatic
diseases, clinically, cover many disorders of the musculoskeletal system which
characterized by the involvement of the joints and periarticular tissues. Oral
mucosal symptoms in rheumatic diseases, has a different significance enough to
enter the diagnostic and classification criteria of some diseases. Drugs and
interactions used in the treatment of this disease, involvement of the oral
mucosa and jaw joint diseases is important for dentists.  In this review it is given general
information on rheumatic diseases and dental approaches.

Keywords: Rheumatic diseases, dentistry, oral health

Keywords

Romatizmal hastalıklar, diş hekimliği

References

• 1. Arend WP, Lawry GV. Appoach to the patient with musculoskeletal disease. In: Goldman L, Schafer AI, editors. Goldman's Cecil Medicine. 24th ed. Philadelphia, Saunders, 2012.1648-51.
• 2. Nurşen D. Romatizmal Hastalıkların Tanımı ve Sınıflandırılması. Türkiye Klinikleri J Immunol Rheumatol 2002;2:3-5.
• 3. Grassi W, De Angelis R, Lamanna G, Cervini C. The clinical features of rheumatoid arthritis. Eur J Radiol 1998;27 Suppl 1:18-24.
• 4. Atsu SS, Ayhan-Ardic F. Temporomandibular disorders seen in rheumatology practices: A review. Rheumatol Int 2006;26:781-7.
• 5. Yazıcı Y, Erkan D. Romatizmal Hastalıklar Tedavi El Kitabı. Ankara, MD Yayıncılık, 2003: 53-64.
• 6. Petty RE, Cassidy JT. Textbook of Pediatric Rheumatology. 5th ed. Philadelphia, Elsevier Saunders Company, 2005;206-341.
• 7. Kasapçopur Ö, Özdoğan H. Jüvenil İdyopatik Artrit. Klinik Gelişim Dergisi 2006;19:7-22.
• 8. Petty R, Southwood TR. Classification of childhood arthritis. Pediatric Rheumatology 1998; 25:1869-70.
• 9. Ronchezel MV, Hilario MO, Goldenberg J, Lederman HM, Faltin K, Jr, de Azevedo MF, Naspitz CK. Temporomandibular joint and mandibular growth alterations in patients with juvenile rheumatoid arthritis. J Rheumatol 1995;22:1956-61.
• 10. Aydın AT. Diz cerrahisi. Ankara, Yeni Fersa Matbaacılık, 1999:5-19.
• 11. Aydın R. Dejeneratif Romatizmal Hastalıklar. İstanbul, Nobel Tıp Kitabevleri, 2000:331-41.
• 12. Okeson JP. Management of temporomandibular disorders and occlusion. 6th ed. St Louis, Mosby-Year Book Inc, 2008:8-15.
• 13. Brooks PM, Day RO. Nonsteroidal antiinflammatory drugs--differences and similarities. N Engl J Med 1991;324:1716-25.
• 14. Vane JR. Introduction: mechanism of action of NSAIDs. Br J Rheumatol 1996;35:11-3.
• 15. Kayaalp S. O. Romatoid Artrite Karşı Kullanılan Özel Antiinflamatuvar İlaçlar: Narkotik Olmayan Analjezikler (Non Steroid Antiinflamatuvar İlaçlar). Tıbbi Farmakoloji, Ankara, Feryal Matbaacılık, 1992:2081-2.
• 16. Conaghan PG, Brooks P. Disease-modifying antirheumatic drugs, including methotrexate, gold, antimalarials, and D-penicillamine. Curr Opin Rheumatol 1995;7:167-73.
• 17. McCune WJ, Vallance DK, Lynch JP. 3rd. Immunosuppressive drug therapy. Curr Opin Rheumatol 1994;6:262-72.
• 18. Day O R. Kelley’s Textbook of Rheumatology. 6th ed. Philadelphia, WB Saunders Com, 2001:853-7.
• 19. Advisory statement. Antibiotic prophylaxis for dental patients with total joint replacements. American Dental Association; American Academy of Orthopaedic Surgeons. J Am Dent Assoc 1997;128:1004-8.
• 20. Healy PJ, Helliwell PS. Classification of the spondyloarthropathies. Curr Opin Rheumatol 2005; 17: 395-9.
• 21. Khan MA. An overview of clinical spectrum and heterogeneity of spondyloarthropathies. Rheum Dis Clin North Am 1992;18:1-10.
• 22. Cooksey R, Brophy S, Gravenor MB, Brooks CJ, Burrows CL, Siebert S. Frequency and charac- teristics of disease flares in ankylosing spondylitis. Rheumatology (Oxford) 2010;49:929-32.
• 23. Braun J, Sieper J. Ankylosing spondylitis. Lancet 2007; 369: 1379-90.
• 24. Amor B. Reiter's syndrome. Diagnosis and clinical features. Rheum Dis Clin North Am 1998;24:677-95.
• 25. Moll JM, Wright V. Psoriatic arthritis. Semin Arthritis Rheum 1973;3:55-78.
• 26. Conroy B, Reitzik M. Prosthetic restoration in microstomia. J Prosthet Dent 1971;26:324-7.
• 27. Oksel F. Klinik Romatoloji El Kitabı. İzmir, İzmir Güven Kitabevi, 2003:237-65.
• 28. Edworty SM. Kelley’s Textbook of Rheumatology. 7th ed. USA, Elsevier Saunders, 2005:1201-3.
• 29. Hahn BH. Harrison’s Principles of İnternal Medicine. 16th ed. London, McGraw-Hill, 2005:1960-8.
• 30. Hahn BH. Kelley’s Textbook of Rheumatology. 7th ed. USA, Elsevier Saunders, 2005:1225-47.
• 31. Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, et al. Classification criteria for Sjogren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002;61:554-8.
• 32. Pedersen AM, Bardow A, Nauntofte B. Salivary changes and dental caries as potential oral markers of autoimmune salivary gland dysfunction in primary Sjogren's syndrome. BMC Clin Pathol 2005;5:4.
• 33. Hamburger J. Sjogren's syndrome as seen by an oral physician. Scand J Rheumatol Suppl 2001;11534-8.
• 34. Samarawickrama DY. Saliva substitutes: how effective and safe are they? Oral Dis 2002;8:177-9.
• 35. Neville BW, Damm DD, Allen CM, Bouquot JE. Oral and maxillofacial pathology. 2nd ed. Philadelphia, W.B. Saunders Co, 2002:137.
• 36. Albilia JB, Lam DK, Blanas N, Clokie CM, Sandor GK. Small mouths .. Big problems? A review of scleroderma and its oral health implications. J Can Dent Assoc 2007;73:831-6.
• 37. Braunwald E, Fauci A, Kasper D, Hauser S, Longo Dan L, Jameson Larry J. Harrison iç hastalıkları prensipleri. İstanbul, Nobel Kitabevi, 2004:1979-2018.
• 38. Saag KG, Choi H. Epidemiology, risk factors, and lifestyle modifications for gout. Arthritis Res Ther 2006;8 Suppl 1:2.
• 39. Liote F, Orcel P. Osteoarticular disorders of endocrine origin. Baillieres Best Pract Res Clin Rheumatol 2000;14:251-76.
• 40. Ball EV. Systemic diseases in which arthritis is a feature. In Goldman L, Bennett JC(eds): Cecil Textbook of Medicine. 21st ed. Philadelphia, WB Saunders, 2000:1556-8.
• 41. Osteoporosis prevention, diagnosis, and therapy. JAMA 2001;285:785-95.
• 42. Göksoy T. Osteoporozda Tanı ve Tedavi. İstanbul, 2000.
• 43. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ Tech Rep Ser 1994;8431:129.
• 44. Albright F, Smith PH, AM R. Postmenopausal osteoporosis: Its clinical features. J Am Med Assoc 1941;1162465-74.
• 45. Hoff AO, Toth BB, Altundag K, Johnson MM, Warneke CL, Hu M, et al. Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosp- honates. J Bone Miner Res 2008;23:826-36.
• 46. Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra B. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaw - 2009 update. Aust Endod J 2009;35:119-30.
• 47. Mucocutaneous lesions of Behçet’s disease. TURKDERM 2003;37:92-9.
• 48. Ghate JV, Jorizzo JL. Behcet's disease and complex aphthosis. J Am Acad Dermatol 1999;40:1-18.
• 49. Yurdakul S, Tüzün Y, Mat MC, Özyazgan Y, H. Y. Dermatoloji. 2.Baskı. İstanbul, Nobel Tıp Kitabevleri, 1994:393-9.
• 50. Mumcu G, Ergun T, Inanc N, Fresko I, Atalay T, Hayran O, Direskeneli H. Oral health is impaired in Behcet's disease and is associated with disease severity. Rheumatology (Oxford) 2004;43:1028-33.
• 51. Leavitt RY, Fauci AS, Bloch DA, Michel BA, Hunder GG, Arend WP, Calabrese LH, Fries JF, Lie JT, Lightfoot RW, Jr., et al. The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis. Arthritis Rheum 1990;33: 1101-7.
• 52. Cimaz R, Falcini F. An update on Kawasaki disease. Autoimmun Rev 2003;2:258-63.
• 53. Fraser GF. Diagnosis of Disease of the Chest,. 4th ed. Philadelphia; W.B.Saunders Company, 1999;3:1533-83.
• 54. Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. Am J Respir Crit Care Med 1999;160:736-55.
• 55. Carapetis JR, McDonald M, Wilson NJ. Acute rheumatic fever. Lancet 2005;366:155-68.
• 56. Guidelines for the diagnosis of rheumatic fever. Jones Criteria, 1992 update. Special Writing Group of the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease of the Council on Cardiovascular Disease in the Young of the American Heart Association. JAMA 1992;268:2069-73.
• 57. Doğan DA. Çocukluk çağı Ailevi Akdeniz Ateşi hastalarında klinik ve epidemiyolojik özelliklerin belirlenmesi ve bu özelliklerle sık görülen mutasyonlar arasındaki ilişkilerin araştırılması. Bilim uzmanlığı tezi, İstanbul Üniversitesi Tıp Fak, İstanbul, 2007.
• 58. Yılmaz S. Ailesel Akdeniz Ateşi'nde böbrek tutulumu. İstanbul Tıp Der 2009;72:71-4.